Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Harnessing advanced data analysis for early detection, prevention and better outcomes
Subscribe To Our Newsletter & Stay Updated
